Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

UGN-301 Shows Early Tolerability in Recurrent Non–Muscle-Invasive Bladder Cancer

April 26th 2025

Continued evaluation of UGN-301 in patients with recurrent NMIBC is warranted.

The OncFive: Top Oncology Articles for the Week of 4/20

April 26th 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

Oncology Experts Preview Top Abstracts From AUA 2025

April 24th 2025

Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.

Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS

April 22nd 2025

Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.

The OncFive: Top Oncology Articles for the Week of 4/13

April 19th 2025

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

FDA Receives sBLA for Nogapendekin Alfa Inbakicept in Papillary NMIBC

April 15th 2025

A sBLA for nogapendekin alfa inbakicept in BCG-unresponsive non–muscle-invasive bladder cancer with papillary disease was submitted to the FDA.

Bladder-Sparing Strategies and ctDNA-Guided Strategies Take Center Stage in MIBC: With Chandler Park, MD; and Vadim Koshkin, MD

April 14th 2025

Drs Park and Koshkin explore the clinical implications of the phase 3 NIAGARA trial for patients with resectable bladder cancer.

Innovative Research Raises Questions About the Role of ADCs in Bladder Cancer: With Chandler Park, MD; and Vadim Koshkin, MD

April 9th 2025

Drs Park and Koshkin discuss sequencing antibody-drug conjugates for bladder cancer and the potential future role of sacituzimab govitecan in this disease.

Bel-Sar Shows Tolerability and Preliminary Antitumor Activity in NMIBC

April 7th 2025

Belzupacap sarotalocan demonstrated a favorable safety profile and early signs of biological activity in patients with NMIBC.

Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology

April 5th 2025

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

April 3rd 2025

Drs Park and Koshkin discuss the benefits of enfortumab vedotin in bladder cancer and the potential for more ADCs to join the treatment paradigm.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 2nd 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Dr Bowman on the Safety of TKI and Immunotherapy Combinations in Non–Clear Cell RCC

March 31st 2025

Dr Bowman discusses immune-related and TKI-specific toxicities when combining immunotherapy and TKIs in non–clear cell RCC.

Five Under 5: Top Oncology Videos for the Week of 3/23

March 30th 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 3/23

March 29th 2025

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

Dr Galsky on the Significance of the FDA Approval of Perioperative Durvalumab Plus Gemcitabine/Cisplatin for MIBC

March 28th 2025

Matthew Galsky, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with muscle-invasive bladder cancer.

FDA Approves Perioperative Durvalumab Plus Chemo for Muscle-Invasive Bladder Cancer

March 28th 2025

The FDA approved perioperative durvalumab plus chemotherapy for muscle-invasive bladder cancer.

Dr Sonpavde on the Ongoing Investigation of V940 Plus Pembrolizumab in High-Risk MIBC

March 26th 2025

Guru P. Sonpavde, MD, discusses the INTerpath-005 study evaluating adjuvant V940 plus pembrolizumab in resected high-risk MIBC.

Dr Tyson on Factors Influencing the Selection of Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

March 25th 2025

Mark D. Tyson, II, MD, MPH, discusses challenges choosing between nadofaragene firadenovec, nogapendekin alfa, and pembrolizumab in BCG-unresponsive NMIBC.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23rd 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.